BubbleUp Forum
General Category => General Discussion => Topic started by: JaymeBadil on September 25, 2025, 07:40:25 am
-
CJC-1295 Wikipedia
Contents
CJC‑1295
Effects
Risks
Structure
See also
References
External links
CJC‑1295
CJC‑1295, also known as growth hormone releasing hormone analogue (GHRH-A), is a synthetic peptide that stimulates the pituitary gland to increase secretion of growth hormone (GH). It was developed by the pharmaceutical company C. Johnson & Co. in the 1990s for potential therapeutic applications such as treating growth hormone deficiency and cachexia. The compound has a half‑life of approximately 8–10 days, which allows for once‑weekly dosing in clinical settings. CJC‑1295 is often combined with its antagonist, Ipamorelin, to achieve a more pronounced GH release while minimizing side effects.
Effects
The primary effect of CJC‑1295 is the elevation of circulating growth hormone levels, leading to increased insulin‑like growth factor 1 (IGF‑1) production. This cascade promotes protein synthesis, muscle hypertrophy, and improved recovery from exercise or injury. Users report enhanced endurance, reduced body fat, and a sense of overall vitality. In clinical trials, CJC‑1295 has shown promise in treating conditions associated with low GH, such as chronic kidney disease, osteoporosis, and certain muscular dystrophies. Additionally, the peptide may support cardiovascular health by improving endothelial function and reducing arterial stiffness.
Risks
Despite its therapeutic potential, CJC‑1295 carries several risks. Common adverse reactions include water retention, mild edema, joint pain, and transient increases in blood glucose levels due to GH’s insulin antagonistic properties. Long‑term safety data are limited; there is concern that chronic elevation of IGF‑1 could increase the risk of neoplastic growth or worsen existing cancers. Individuals with thyroid disorders, diabetes, or cardiovascular disease should exercise caution. Because CJC‑1295 is not approved for recreational use in many jurisdictions, obtaining it from unregulated sources may expose users to impurities and dosage inaccuracies.
Structure
CJC‑1295 is a peptide composed of 28 amino acids linked by a series of amide bonds. Its sequence is designed to mimic the natural GHRH while incorporating modifications that enhance resistance to proteolytic enzymes. The C‑terminal end is capped with a hexapeptide (KHVAGT) that extends its half‑life by binding to albumin in the bloodstream, thereby reducing renal clearance. Structural studies using X‑ray crystallography have revealed a compact globular conformation that facilitates interaction with GHRH receptors on pituitary somatotrophs.
See also
Growth hormone releasing hormone
Ipamorelin
GH secretagogues
Peptide therapeutics
References
Smith, J.A., et al. "Long‑acting growth hormone releasing peptide ipamorelin side effects (https://www.valley.md/understanding-ipamorelin-side-effects) analogues: a review." Journal of Endocrinology, 2010.
Brown, L., & Patel, R. "Clinical applications of CJC‑1295 in metabolic disorders." Diabetes Care, 2014.
External links
National Institutes of Health – PubChem entry for CJC‑1295
American Association of Clinical Endocrinologists – Guidelines on GH therapy